These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11870257)

  • 21. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.
    Yamasawa H; Sugiyama Y; Bando M; Ohno S
    Respiration; 2008; 75(3):350-4. PubMed ID: 16449804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythema following imatinib mesylate.
    Duncan E; Raj K; Mufti G
    Br J Haematol; 2003 Jul; 122(1):1. PubMed ID: 12823338
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty.
    Mariani S; Basciani S; Fabbri A; Agati L; Ulisse S; Lubrano C; Spera G; Gnessi L
    Fertil Steril; 2011 Mar; 95(3):1120.e15-7. PubMed ID: 20888557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.
    Pieri L; Bosi A; Vannucchi AM
    Ann Hematol; 2010 Jul; 89(7):745-6. PubMed ID: 19953254
    [No Abstract]   [Full Text] [Related]  

  • 25. Pseudoporphyria induced by imatinib mesylate.
    Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
    Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
    [No Abstract]   [Full Text] [Related]  

  • 26. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.
    Tefferi A; Mesa RA; Gray LA; Steensma DP; Camoriano JK; Elliott MA; Pardanani A; Ansell SM; Call TG; Colon-Otero G; Schroeder G; Hanson CA; Dewald GW; Kaufmann SH
    Blood; 2002 May; 99(10):3854-6. PubMed ID: 11986248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib induced pyoderma gangrenosum.
    Pinato DJ; Sharma R
    J Postgrad Med; 2013; 59(3):244-5. PubMed ID: 24029213
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse events after imatinib mesylate therapy.
    Burton C; Azzi A; Kerridge I
    N Engl J Med; 2002 Feb; 346(9):712-3. PubMed ID: 11873781
    [No Abstract]   [Full Text] [Related]  

  • 30. Need for the appraisal of uncommon side effects of a commonly prescribed drug- Imatinib.
    Attili V; Anuradha V; Raju S
    Indian J Cancer; 2008; 45(2):72. PubMed ID: 18626154
    [No Abstract]   [Full Text] [Related]  

  • 31. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 32. A rare case of imatinib-induced erythroderma.
    Verma R; Vasudevan B; Pragasam V; Neema S
    Indian J Pharmacol; 2013; 45(6):634-5. PubMed ID: 24347779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase.
    Gogtay J; Chahchad S; Jadhav S; Purandare S
    Int J Hematol; 2010 Dec; 92(5):772-3. PubMed ID: 21082296
    [No Abstract]   [Full Text] [Related]  

  • 34. Lichenoid eruption due to imatinib.
    Prabhash K; Doval DC
    Indian J Dermatol Venereol Leprol; 2005; 71(4):287-8. PubMed ID: 16394444
    [No Abstract]   [Full Text] [Related]  

  • 35. Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
    Yalamanchili K; Liu D; Seiter K
    Leukemia; 2007 Mar; 21(3):577-8. PubMed ID: 17230224
    [No Abstract]   [Full Text] [Related]  

  • 36. [Successful induction of complete cytogenetic response with low-dose imatinib mesylate in an accelerated phase chronic myelogenous leukemia patient who developed severe bone marrow aplasia following standard-dose imatinib mesylate therapy].
    Nakazato T; Suzuki K; Mihara A; Sanada Y; Kakimoto T
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):539-42. PubMed ID: 20332700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe hemolytic anemia and skin reaction in a patient treated with imatinib.
    De Arriba JJ; Nerín C; García E; Gómez-Aldaraví L; Vila B
    Ann Oncol; 2003 Jun; 14(6):962. PubMed ID: 12796039
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib mesylate-induced interstitial pneumonitis.
    Ma CX; Hobday TJ; Jett JR
    Mayo Clin Proc; 2003 Dec; 78(12):1578-9. PubMed ID: 14661689
    [No Abstract]   [Full Text] [Related]  

  • 39. Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib.
    Salmons N; Gregg RJ; Pallalau A; Woolhouse I; Geh I; Tanière P
    J Clin Pathol; 2007 Feb; 60(2):199-201. PubMed ID: 17264244
    [No Abstract]   [Full Text] [Related]  

  • 40. Nonhematologic toxicity of imatinib mesylate in pediatric patients with chronic myelogenous leukemia: a predominance of musculoskeletal pain.
    Heym KM; Gressett Ussery SM; Trinkman H; Philpot LM
    J Pediatr Hematol Oncol; 2015 Mar; 37(2):e111-3. PubMed ID: 25374285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.